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Background: Although endovascular therapy (EVT) has advanced, few reported the long-term outcome in aortoiliac CTO lesion. The purpose of this 
study was to evaluate outcomes of EVT for aortoiliac CTO lesion.
Methods: Retrospective analysis of 437 patients (Male 81%, mean follow-up 947±536 days) who underwent aortoiliac stenting in 540 limbs, and 
there were 121 CTO and 419 non-CTO lesions. The primary patency rates of CTO and non-CTO lesions were analyzed by Kaplan-Meier methods and 
compared by the log rank test. Using Cox proportional-hazards model, factors through univariate analysis (P < 0.2) were tested in a multivariable 
analysis for association with primary patency rate.
Results: The primary technical success rate was achieved in 97.6% with an overall complication rate of 3.3% in CTO lesion. The 1 and 5 year 
primary patencies of the iliac stenting were 96% and 92% in CTO lesion; 97% and 89% in non-CTO lesion, and there was no significant difference 
in primary patency rate between CTO and non-CTO lesion by the log rank test. Furthermore, Trans-Atlantic Inter-Society Consensus (TASC)-II 
classification and lesion length were not significant factors associated with primary patency rate in CTO lesion.
Conclusions: In conclusion, there was no significant difference in patency rate between aortoiliac CTO and non-CTO lesion, and primary stent 
placement for aortoiliac CTO lesion was safe and acceptable, regardless TASC-II classification or lesion length.
 
